Conjugated equine estrogens and coronary heart disease: The women's health initiative

Archives of Internal Medicine

Volumn 166, Issue 3, 2006, Pages 357-365

  Hsia, Judith ^a   Langer, Robert D ^b   Manson, JoAnn E ^c   Kuller, Lewis ^d   Johnson, Karen C ^e   Hendrix, Susan L ^f   Pettinger, Mary ^g   Heckbert, Susan R ^h   Greep, Nancy ⁱ   Crawford, Sybil ^j   Eaton, Charles B ^k   Kostis, John B ^l   Caralis, Pat ^m   Prentice, Ross ^g  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f HUTZEL HOSPITAL   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^k BROWN UNIVERSITY   (United States)

^l ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGE DISTRIBUTION; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; TRIGLYCERIDES; UNITED STATES;

EID: 32644436832     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.3.357     Document Type: Article

References (25)

1. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Manson JE, Hsia J, Johnson KC, et al; Women's Health Initiative Investigators. Estrogen plus progestin and risk of CHD. N Engl J Med. 2003;349:523-534.
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen on postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
5. Hays J, Hunt JR, Hubbell A, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13:S18-S77.
6. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13:S78-S86.
7. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative Study Design. Ann Epidemiol. 2003;13:S5-S17.
8. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13:S122-S128.
9. Hsia J, Aragaki A, Bloch M, LaCroix AZ, Wallace R. Predictors of angina vs myocardial infarction from the Women's Health Initiative. Am J Cardiol. 2004;93:673-678.
10. Schoenfeld DA. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68:316-319.
11. Hsia J, Barad D, Margolis K, et al; Women's Health Initiative Research Group. Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (The Women's Health Initiative). Am J Cardiol. 2003;92:264-269.
12. Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative observational study. Circulation. 2005;111:1462-1470.
13. Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004;81:1498-1501.
14. Lemay A. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can. 2002;24:711-715.
15. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol. 2004;24:1171-1179.
16. Hulley S, Grady D, Bush T, et al; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of CHD in postmenopausal women. JAMA. 1998;280:605-613.
17. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 2005;273:199-208.
18. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation. 1999;100:717-722.
19. Clarkson TB, Appt SE. MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids. 2003;68:941-951.
20. Herrington D, Reboussin DM, Brosnihan B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
21. Hodis HN, Mack WJ, Azen SP, et al; Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-545.
22. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.
23. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
24. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645-650.
25. Berger L. Two years after; on hormone therapy, the dust is still settling. New York Times. June 6, 2004;15:1.